This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, L.-X. Articles by Plautz, G. E. Search for Related Content PubMed PubMed Citation Articles by Wang, L.-X. Articles by Plautz, G. E.

Host Lymphodepletion Augments T Cell Adoptive Immunotherapy through Enhanced Intratumoral Proliferation of Effector Cells

Center for Surgery Research, Division of Surgery, Cleveland Clinic Foundation, Cleveland, Ohio

Requests for reprints: Gregory Plautz, Center for Surgery Research FF5, 9500 Euclid Avenue, Cleveland, OH 44195. Phone: 216-445-3800; Fax: 216-445-3805; E-mail: plautzg{at}ccf.org.

T-cell adoptive immunotherapy for stringent murine tumor models, such as intracranial, s.c., or advanced pulmonary metastases, routinely uses lymphodepletive conditioning regimens before T-cell transfer, like recent clinical protocols. In this study, we examined whether host lymphodepletion is an obligatory component of curative T-cell therapy; we also examined the mechanism by which it augments therapy. Mice bearing intracranial, s.c., or 10-day pulmonary metastases of MCA 205 received total body irradiation conditioning or were nonirradiated before i.v. transfer of tumor-reactive T cells. Total body irradiation was not required for immunologically specific curative therapy and induction of memory provided that a 3- to 12-fold higher T-cell dose was administered. The mechanism involved enhanced intratumoral proliferation of T-effector cells in total body irradiation–conditioned recipients. In this tumor model, intratumoral T_reg cells were not detected; consequently, intratumoral T-effector cells produced identical amounts of IFN- upon ex vivo antigen stimulation irrespective of total body irradiation conditioning. Thus, host lymphodepletion augments T-cell immunotherapy through enhanced antigen-driven proliferation of T-effector cells, but curative therapy can be achieved in nonconditioned hosts by escalation of T-cell dose. These data provide a rationale for dose escalation of T-effector cells in situations where single or repeated lymphodepletion regimens are contraindicated.

This article has been cited by other articles:

				H. S. Kim, S. Kim-Schulze, D. W. Kim, and H. L. Kaufman Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand Cancer Res., November 1, 2009; 69(21): 8516 - 8525. [Abstract] [Full Text] [PDF]

				D. L. Thomas, M. Kim, N. A. Bowerman, S. Narayanan, D. M. Kranz, H. Schreiber, and E. J. Roy Recurrence of Intracranial Tumors following Adoptive T Cell Therapy Can Be Prevented by Direct and Indirect Killing Aided by High Levels of Tumor Antigen Cross-Presented on Stromal Cells J. Immunol., August 1, 2009; 183(3): 1828 - 1837. [Abstract] [Full Text] [PDF]

				M. Saini, C. Pearson, and B. Seddon Regulation of T cell-dendritic cell interactions by IL-7 governs T-cell activation and homeostasis Blood, June 4, 2009; 113(23): 5793 - 5800. [Abstract] [Full Text] [PDF]

				A. M. Tatum, L. M. Mylin, S. J. Bender, M. A. Fischer, B. A. Vigliotti, M. J. Tevethia, S. S. Tevethia, and T. D. Schell CD8+ T Cells Targeting a Single Immunodominant Epitope are Sufficient for Elimination of Established SV40 T Antigen-Induced Brain Tumors J. Immunol., September 15, 2008; 181(6): 4406 - 4417. [Abstract] [Full Text] [PDF]

				J. King, J. Waxman, and H. Stauss Advances in tumour immunotherapy QJM, September 1, 2008; 101(9): 675 - 683. [Abstract] [Full Text] [PDF]

				S. Watanabe, K. Deguchi, R. Zheng, H. Tamai, L.-x. Wang, P. A. Cohen, and S. Shu Tumor-Induced CD11b+Gr-1+ Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes J. Immunol., September 1, 2008; 181(5): 3291 - 3300. [Abstract] [Full Text] [PDF]

				A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda Transforming Growth Factor-{beta} Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers Clin. Cancer Res., June 15, 2008; 14(12): 3966 - 3974. [Abstract] [Full Text] [PDF]

				A. Jorritsma, A. D. Bins, T. N.M. Schumacher, and J. B.A.G. Haanen Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer Cancer Res., April 1, 2008; 68(7): 2455 - 2462. [Abstract] [Full Text] [PDF]

				M. J. Pittet, J. Grimm, C. R. Berger, T. Tamura, G. Wojtkiewicz, M. Nahrendorf, P. Romero, F. K. Swirski, and R. Weissleder In vivo imaging of T cell delivery to tumors after adoptive transfer therapy PNAS, July 24, 2007; 104(30): 12457 - 12461. [Abstract] [Full Text] [PDF]

				F. Masson, T. Calzascia, W. Di Berardino-Besson, N. de Tribolet, P.-Y. Dietrich, and P. R. Walker Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells J. Immunol., July 15, 2007; 179(2): 845 - 853. [Abstract] [Full Text] [PDF]

				L.-X. Wang, S. Shu, M. L. Disis, and G. E. Plautz Adoptive transfer of tumor-primed, in vitro activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response Blood, June 1, 2007; 109(11): 4865 - 4876. [Abstract] [Full Text] [PDF]

				U. Thanarajasingam, L. Sanz, R. Diaz, J. Qiao, L. Sanchez-Perez, T. Kottke, J. Thompson, J. Chester, and R. G. Vile Delivery of CCL21 to Metastatic Disease Improves the Efficacy of Adoptive T-Cell Therapy Cancer Res., January 1, 2007; 67(1): 300 - 308. [Abstract] [Full Text] [PDF]